Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 3/20 | 0.58 |
| ▸ | HTR7 | P34969 | 2/20 | 0.49 |
| ▸ | HTR3A | P46098 | 8/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.49 |
| ▸ | HTR3B | O95264 | 1/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 7/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29805912 | 0.81 | HTR1A (0.62) | ADRB1HTR7HTR3AHTR6HTR1A | |
| SCHEMBL255418 | 0.81 | HTR1A (0.62) | ADRB1HTR7HTR3AHTR6HTR1A | |
| Hydrochloric Acid SCHEMBL2959720 | 0.80 | HTR1A (0.65) | ADRB1HTR7HTR3AHTR6HTR1A | |
| SCHEMBL25719100 | 0.80 | HTR6 (0.47) | HTR3AHTR6HTR1A | |
| SCHEMBL23339696 | 0.79 | ALDH1A1 (0.45) | ADRB1HTR7HTR3AHTR3EHTR3B | |
| SCHEMBL30080727 | 0.79 | HTR3A (0.64) | ADRB1HTR7HTR3AHTR3EHTR3B | |
| SCHEMBL6580339 | 0.79 | ADRB1 (0.59) | ADRB1HTR7HTR3AHTR3EHTR3B | |
| SCHEMBL4238177 | 0.79 | ADRB1 (0.58) | ADRB1HTR7HTR3AHTR3EHTR3B | |
| SCHEMBL255186 | 0.79 | HTR3A (0.64) | ADRB1HTR7HTR3AHTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL19385628 | 0.77 | HTR3A (0.62) | ADRB1HTR7HTR3AHTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| EP-1205473-A1 | VESAMICOL PIPERAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | DAIICHI RADIOISOTOPE LABORATORIES, LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | SPHK1, SPHK2, S1PR3 | ADRB1 437/4885HTR7 1316/4885HTR3A 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.